Instytut Psychiatrii i Neurologii

What Instytut Psychiatrii i Neurologii does

Instytut Psychiatrii i Neurologii (IPiN) is a state-funded national research institute under the Polish Ministry of Health, headquartered in Warsaw at ul. Sobieskiego 9, and self-described as the largest psychiatric and neurological research center in Poland. The institute integrates three primary functions within a single campus: (1) clinical care, delivered through multiple inpatient psychiatric and neurological wards, day hospitals, specialized outpatient clinics (including Mental Health, Neurology, Neurosurgery, Genetics, and Addiction Treatment), a stroke unit with thrombectomy capability, and a 24-hour neurological rehabilitation ward; (2) basic and clinical research, organized across dedicated departments covering genetics, neurochemistry, clinical neurophysiology, neuropathology, pharmacology and physiology of the nervous system, radiology, and public health, plus animal-model research using the proprietary Warsaw High-Preferring (WHP) alcohol-preferring rat line; and (3) publishing and education, operated through Wydawnictwo IPiN, which produces three peer-reviewed journals (Postępy Psychiatrii i Neurologii, Farmakoterapia w Psychiatrii i Neurologii, Alkoholizm i Narkomania) and therapeutic/prevention programs.

The technology stack includes EEG, polysomnography, EMG, MRI, CT, Doppler ultrasound, and an EMQN-certified molecular genetics laboratory serving as Poland's reference lab for the European Huntington Disease Network (Enroll-HD), TREAT-NMD, EUROSCA, and the European Reference Network for Rare Neurological Diseases (ERN-RND). Treatment modalities span electroconvulsive therapy (Thymatron-System-IV), repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation for Parkinson's, epilepsy, and dystonia, and clinical trials including a randomized placebo-controlled study on low-dose aspirin adjunct therapy for bipolar disorder. The institute is rolling out AI-powered mobile applications that analyze voice parameters, daily activity, and sleep quality to detect relapse precursors in affective disorder patients.

IPiN's revenue is generated through four streams: (1) National Health Fund (NFZ) contracts for inpatient, outpatient, and emergency psychiatric and neurological services; (2) EU-funded research and program grants, including the 257,164,386.41 PLN FERS.04.15-IP.07-0006/24 project (Dec 2024 - Jul 2028) covering 20 specialized mental health programs, 5,000 patients, and training for 880 healthcare professionals; (3) commercial diagnostic services for patients and institutions outside the NFZ system, particularly specialized genetic and neuroimaging tests; and (4) publishing revenue from scientific monographs, journals, and structured prevention programs (e.g., Program Domowych Detektywów, Program Fantastyczne Możliwości). Pricing is largely public-sector reimbursement, with limited unit-pricing on ancillary services (e.g., 20-25 PLN per day for student internships). Leadership is appointed by the Minister of Health; the current Director, Sylwia Szepelawa, was appointed on 2025-01-31.

Name

Instytut Psychiatrii i Neurologii

Legal name

Instytut Psychiatrii i Neurologii

Website

https://ipin.edu.pl

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Instytut Psychiatrii i Neurologii is a Polish state-funded national research institute under the Ministry of Health and the country's largest psychiatric and neurological research center, delivering integrated clinical care, basic and clinical research, scientific publishing, and training to Polish patients with psychiatric and neurological disorders.

Ownership category

akta.pro rank

Product category

Psychiatric and Neurological Healthcare Services

NAICS

Psychiatric and Substance Abuse Hospitals (622210), Offices of Physicians, Mental Health Specialists (621112), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (6215)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAFACAB

Inpatient Psychiatric Hospitals & Units

Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment

SECONDARYHLAFAHAH

Inpatient Psychiatric Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

SECONDARYHLAKAIAO

Neurogenetics & Rare Neurologic Diseases

Healthcare & Life Sciences/Specialist Medical Practice/Neurology

SECONDARYHLAFAFAH

Neurorehabilitation Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Post-Acute Care & Rehabilitation Facilities

SECONDARYHLAKAIAH

Cognitive & Behavioral Neurology (Dementia/Memory Disorders)

Healthcare & Life Sciences/Specialist Medical Practice/Neurology

Keywords

• Psychiatric treatment services
• Neurological care services
• Medical diagnostic services
• Clinical research institute
• Mental health rehabilitation

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. National Health Fund (NFZ) Contracts: Primary revenue stream from contracted healthcare services covered by the Polish public health insurance system. The institute provides inpatient and outpatient psychiatric and neurological care reimbursed by NFZ.
2. EU Funded Research Projects: European funding from FERS (European Social Fund+) for specialized mental health diagnosis and treatment programs. Project FERS.04.15-IP.07-0006/24 valued at 257,164,386.41 PLN.
3. Commercial Diagnostic Services: Fee-for-service diagnostic testing including specialized genetic tests, neuroimaging, and neurophysiological studies for patients outside the NFZ system.
4. Publishing and Educational Materials: Revenue from the institute's publishing house selling scientific books, journals, and prevention program materials in psychiatry, neurology, and addiction fields.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Instytut Psychiatrii i Neurologii is Poland's largest psychiatric and neurological research and treatment center. It delivers inpatient and outpatient psychiatric and neurological care, comprehensive diagnostics (neuroimaging, neurophysiology, genetic testing, neuropsychology), rehabilitation services, and clinical research. The institute also runs a scientific publishing house producing peer-reviewed journals and prevention programs in psychiatry, neurology, and addiction medicine.

Product overview

Instytut Psychiatrii i Neurologii (IPiN) is Poland's largest scientific center specializing in developing new methods for treating and rehabilitating psychiatric and neurological disorders. The institution operates as a unified healthcare complex offering hospital treatment, outpatient clinic services, and diagnostics, supported by its publishing division (Wydawnictwo IPiN) which produces scientific monographs, prevention programs (Program Domowych Detektywów, Program Fantastyczne Możliwości), and clinical training materials. IPiN also conducts extensive clinical research through EU-funded projects developing specialized mental health diagnosis and treatment programs, provides e-registration services for patient access, and offers educational internships and traineeships. The portfolio includes therapeutic publications like Trening: Akceptacja 4FM and various prevention programs addressing depression, suicide, and addiction.

Differentiator

Problem solved

Functional benefit

Brands

• Wydawnictwo IPiN: Publishing house of the Institute of Psychiatry and Neurology, publishing books in psychiatry, neurology, addictions, and mental health; and three scientific journals: Postępy Psychiatrii i Neurologii, Farmakoterapia w Psychiatrii i Neurologii, and Alkoholizm i Narkomania.

Products and services

• Inpatient Hospital Treatment (Leczenie szpitalne) Inpatient psychiatric and neurological treatment services including acute care, specialized therapy programs, and intensive monitoring for patients with mental health and neurological disorders. Services are delivered across multiple inpatient wards (F1, F2, F4, F5, F6, F7, F9, F10), neurology wards, neurosurgery department, and neurological rehabilitation.
• Outpatient Clinic Treatment (Leczenie w poradni) Ambulatory psychiatric and neurological consultation services across multiple specialized clinics including the Mental Health Clinic (ZPPS), Neurological Clinic, Neurosurgical Clinic, Genetic Clinic, Addiction Treatment Clinic, Child and Adolescent Mental Health Clinic, and Sleep Disorder Clinic.
• Diagnostic Services (Diagnostyka) Comprehensive diagnostic services including neuroimaging (MRI, CT, Doppler ultrasound), neurophysiology (EEG, EMG, polysomnography), neuropsychological assessment, EMQN-certified genetic testing for neurodegenerative diseases (Huntington's disease, spinocerebellar ataxias, muscular dystrophies), and specialized laboratory diagnostics.
• Deep Brain Stimulation (DBS) Surgical treatment using implanted electrodes for Parkinson's disease, dystonia, essential tremor, and drug-resistant epilepsy. Provided by the Neurosurgery Department.
• Electroconvulsive Therapy (ECT) Modern ECT treatment performed under general anesthesia with muscle relaxants using the Thymatron-System-IV for psychiatric disorders.
• Transcranial Magnetic Stimulation (rTMS) Non-invasive transcranial magnetic stimulation for treatment of psychiatric conditions.
• Specialist Mental Health Diagnosis and Treatment Programs (Specjalistyczne programy diagnozy i leczenia zaburzeń psychicznych) EU-funded program developing 20 specialized programs for diagnosis and treatment of mental disorders, covering dual diagnosis, autism spectrum disorders, OCD, bipolar disorder, personality disorders, depression, psychosis, ADHD, eating disorders, behavioral addictions, and substance use disorders. Target enrollment: 5,000 patients; staff training: 880 professionals.
• Internships and Traineeships (Praktyki i staże) Educational programs for medical students, psychology trainees, and physicians including basic internships, partial/personalized internships, specialized internships, and post-graduate traineeships across psychiatry, neurology, and neurosurgery departments. Student practice fee: 25 PLN/day; postgraduate internship fee: 20 PLN/day.
• Clinical Trial: Low-Dose Aspirin for Bipolar Disorder (Badanie 2021/ABM/02/00008) Randomized double-blind placebo-controlled clinical trial evaluating low-dose aspirin as adjunct treatment for bipolar disorder patients on standard therapy.
• Wydawnictwo IPiN (IPiN Publishing House) Publishing division producing scientific books, monographs, and journals in psychiatry, neurology, addiction studies, and mental health. Publishes three scientific journals: Postępy Psychiatrii i Neurologii (Impact Factor 1.0), Alkoholizm i Narkomania (Impact Factor 0.3), and Farmakoterapia w Psychiatrii i Neurologii (MNiSW 20). Listed on the ministerial list of publishers of reviewed scientific monographs (80 points, level I).
• Trening: Akceptacja 4FM Training Program Twelve-week therapeutic training program for meaning-seeking using existential methods, based on Alfried Längle's model of fundamental existential motivations. Includes facilitator guidebook and participant workbook, available as a PDF package.
• Program Domowych Detektywów (Home Detectives Program) Evidence-based prevention program distributed by IPiN Publishing for youth mental health promotion and problem behavior prevention.
• Program Fantastyczne Możliwości (Fantastic Opportunities Program) Prevention program distributed by IPiN Publishing for youth mental health and problematic behavior prevention.

Quantifiable outcome

• 20 specialized mental health programs to be developed and implemented
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Specjalistyczny Psychiatryczny Zespół Opieki Zdrowotnej w Łodzi (SPZOZ Łódź)coreStrategic or Co-development Partner · 1 December 2024Partnership in EU-funded project FERS.04.15-IP.07-0006/24 'Development and Implementation of Specialized Mental Health Diagnosis and Treatment Programs'. SPZOZ Łódź will develop 9 programs (2 for adults, 7 for children/youth) and implement programs at their facilities in Łódź. Both institutions will operate Consultation-Coordination Points and train 880 healthcare professionals combined.
• Narodowy Instytut Zdrowia Publicznego PZH – PIBminorStrategic or Co-development PartnerCollaboration for operation of Consultation-Coordination Point at Powsińska 61, 02-903 Warszawa. Part of the EU-funded mental health project network.
• European Reference Network on Rare Neurological Diseases (ERN-RND)coreStrategic or Co-development PartnerIPiN participates in ERN-RND as a center contributing to European network for rare neurological diseases, enabling collaboration on diagnosis and treatment standards.
• European Huntington Disease Network (EHDN)coreStrategic or Co-development PartnerIPiN serves as reference laboratory for EHDN Registry (Enroll-HD) in Poland, performing molecular analyses for Huntington's disease patients registered in the European network.
• TREAT-NMD (Translational Research in Europe - Assessment and Treatment of Neuromuscular Diseases)coreStrategic or Co-development PartnerInternational network for neuromuscular diseases research. IPiN contributes to global database of neuromuscular disease patients for new therapy development.
• EUROSCA (European Spinocerebellar Ataxia Consortium)coreStrategic or Co-development PartnerEuropean consortium for spinocerebellar ataxia research. IPiN participates in molecular, clinical, and basic research aimed at developing effective treatments.
• SCA GlobalminorStrategic or Co-development PartnerInternational organization of centers conducting spinocerebellar ataxia research.
• Ataxia Study Group (ASG)minorStrategic or Co-development PartnerInternational network of academic and research centers collaborating on ataxia research, training, and knowledge dissemination.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Max Planck Institute of Psychiatry: German research institute focused on psychiatric and stress-related disorders, combining basic research with clinical translation. Comparable in the integration of psychiatric research, genetic and molecular studies, and treatment development that mirrors IPiN's research-clinical hybrid model.
• Netherlands Institute for Neuroscience: Dutch research institute focused on fundamental and clinical neuroscience, including psychiatric and neurological disease mechanisms. Comparable in neuroscience research orientation and integration with clinical neurology and psychiatry, but with research rather than direct clinical-care emphasis.

Broad incumbents

• King's College London – Institute of Psychiatry, Psychology & Neuroscience (IoPPN): Leading European institute for psychiatry and neuroscience research and clinical training, with affiliated South London and Maudsley NHS Trust providing clinical services. Comparable in combining psychiatric and neurological research, clinical service delivery, graduate training, and participation in major European research consortia.
• National Institute of Mental Health (NIMH): U.S. federal agency for mental health research, the global benchmark for government psychiatric research institutes. Comparable in being a publicly funded national institute integrating psychiatric research, clinical trials, and translation of findings into practice, though operating at vastly larger scale and budget.
• Medizinische Hochschule Hannover (MHH) – Clinic for Psychiatry, Social Psychiatry and Psychotherapy: Major German university hospital with substantial departments of psychiatry and neurology. Comparable in offering integrated psychiatric/neurological inpatient and outpatient care with strong research output and participation in national and European research networks.
• Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals with major departments of psychiatry and neurology, integrating clinical care, research, and teaching. Comparable in combining specialty inpatient psychiatric/neurological services, large research output, and European Reference Network participation, but at substantially larger scale and broader scope.
• Karolinska Institutet Department of Neuroscience: Swedish medical university's neuroscience department with affiliated clinical neuroscience research. Comparable in translational neuroscience and rare neurological disease research, though primarily academic rather than operating as a clinical service provider like IPiN.

Direct peers

• Ste-Anne Hospital (GHU Paris Psychiatrie & Neurosciences): Historic French university hospital dedicated exclusively to psychiatry and neurosciences, integrating inpatient, outpatient, and research functions. Closely comparable in being a single-specialty public hospital complex with strong research output and historical reputation in mental health and neurology.
• Specjalistyczny Psychiatryczny Zespół Opieki Zdrowotnej w Łodzi (SPZOZ Łódź): Polish specialized psychiatric healthcare facility that is IPiN's official FERS project partner, jointly developing specialized mental health diagnosis and treatment programs. Operates psychiatric inpatient and outpatient services in Poland, directly comparable in scope and public-system funding model.

Regional players

• Mazowieckie Centrum Neuropsychiatrii: Polish specialty psychiatric and neurological hospital and research center serving the Mazowieckie voivodeship. Operates inpatient and outpatient services in the same clinical domains as IPiN, making it the most direct domestic counterpart for regional psychiatric/neurological care and research competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IPiN_Warszawa
• Facebookfacebook.com/InstytutPsychiatriiiNeurologii

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instytut Psychiatrii i Neurologii